Value of 18F-FET PET in Patients With Suspected Tumefactive Demyelinating Disease—Preliminary Experience From a Retrospective Analysis
Value of 18F-FET PET in Patients With Suspected Tumefactive Demyelinating Disease—Preliminary Experience From a Retrospective Analysis
复制标题
18F-FET PET 对疑似肿瘤性脱髓鞘疾病患者的价值——回顾性分析的初步经验
DOI：
--
复制
发表时间：
2018
影响因子：
10.6
通讯作者：
M. Huellner
中科院分区：
文献类型：
--
作者：
M. Barbagallo;A. Albatly;S. Schreiner;Helen Hayward;A. Buck;S. Kollias;M. Huellner
目的探讨18F-氟乙基-L-酪氨酸（FET）正电子发射断层扫描（PET）对疑似肿瘤性脱髓鞘病的诊断价值。方法回顾性分析21例（男9例，女12例）临床诊断为脱髓鞘疾病及新诊断的肿瘤样病变患者的PET和MRI表现。计算病灶的最大标准摄取值（SUVmax）、时间放射性曲线（TAC）和病灶与背景比值（TBR）。参考标准包括活检和/或随访成像。采用Mann-Whitney U检验和受试者工作特征（ROC）分析比较真实肿瘤性病变和肿胀性脱髓鞘病变的FET参数。结果肿瘤性病变9例（42.9%），肿胀性脱髓鞘病变12例（57.1%）。脱髓鞘病变和肿瘤性病变之间的TBRmax、SUVmax和TAC显著不同：肿瘤的TBRmax（分别为3.53 ± 1.09 vs. 1.48 ± 0.31; P < 0.001）和SUVmax（分别为3.95 ± 1.59 vs. 1.86 ± 0.50; P < 0.001）高于肿胀性脱髓鞘病变。肿瘤的TAC在各时间点均显著高于肿胀性脱髓鞘病变（P < 0.05）。ROC分析显示，TBRmax阈值为2.2和SUVmax阈值为2.5可以可靠地区分肿瘤和肿胀性脱髓鞘（曲线下面积分别为1.000和0.958）。结论在脱髓鞘疾病患者中，FET-PET参数TBRmax（临界值2.2）和SUVmax（临界值2.5）能够区分肿瘤性脱髓鞘病变和真正的肿瘤性病变。
Purpose To investigate the diagnostic value of 18F-fluoroethyl-L-tyrosine (FET) positron emission tomography (PET) in patients with suspected tumefactive demyelinating disease. Methods We retrospectively examined FET-PET and MR imaging of 21 patients (12 female, 9 male) with known demyelinating disease and newly diagnosed tumefactive lesions. The maximum standardized uptake value (SUVmax), time activity curves (TAC) and lesion-to-background ratio (TBR) of these lesions were calculated. The standard of reference consisted of biopsy and/or follow-up imaging. FET parameters of true neoplastic lesions and tumefactive demyelinating lesions were compared using Mann-Whitney U-test and receiver operating characteristic (ROC) analysis. Results Nine patients (42.9%) had neoplastic lesions, 12 patients (57.1%) had tumefactive demyelinating lesions. TBRmax, SUVmax and TAC were significantly different between demyelinating lesions and neoplastic lesions: Tumors had a higher TBRmax (3.53 ± 1.09 vs. 1.48 ± 0.31, respectively; P < 0.001) and SUVmax (3.95 ± 1.59 vs. 1.86 ± 0.50, respectively; P < 0.001) than tumefactive demyelinating lesions. The TAC of tumors was significantly higher compared to tumefactive demyelinating lesions at all time points (P < 0.05). ROC analysis revealed that a TBRmax threshold of 2.2 and a SUVmax threshold of 2.5 could reliably differentiate tumor and tumefactive demyelination (area under the curve, 1.000 and 0.958, respectively). Conclusion In patients with demyelinating disease, FET-PET parameters TBRmax (cut-off 2.2) and SUVmax (cut-off 2.5) are able to distinguish tumefactive demyelinations from true neoplastic lesions.
DOI：
--
发表时间：
1999-09
期刊：
AJNR. American journal of neuroradiology
影响因子：
--
作者：
A. Tievsky;T. Ptak;J. Farkas
通讯作者：
A. Tievsky;T. Ptak;J. Farkas